Search Results

GC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals on June 7-8th at Waltham, Massachusetts as a sponsor to share keynote presentation, present Korean Scientist Awards and conduct global recruitment.

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, highlights the commentary of Mittul Mehta, Tevogen’s Chief Information Officer and Head of Tevogen.AI, at the Longwood Spring MIT Conference.

In this short teaser, BioSpace’s Head of Insights Lori Ellis talks to CBER Director Peter Marks and Tom Whitehead, Co-Founder of the Emily Whitehead Foundation about anticipated discussions at the upcoming GenScript Biotech Forum.

Big Pharma can’t seem to get enough radiopharmaceutical biotechs. With Lilly, Sanofi and BMS chasing Novartis into the complex space, all eyes are on these specialty biotechs.

Orbis emerged from stealth in February 2024 with $28.1 million in seed funding. The Danish biotech, which aims to flip biologics into oral medicines, has now raised another $93 million.

The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) with Eli Lilly’s expertise in R&D—plus half a billion in capital from the Big Pharma.

Daxor Corporation announces today it will be exhibiting at the MedAxiom CV Transforum Spring’24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024.